The aim of the study by McGee et al. was to estimate breast cancer risk and all-cause mortality after ovarian cancer in BRCA1/BRCA2 carriers in order to simulate the impact of providing MRI or risk-reducing mastectomy subsequent to ovarian cancer diagnosis. The gene discussed is BRCA2; the disease is breast cancer.